Mural Oncology plc

MURA

IE000LK2BOB4

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-07 EDT			5-day change	1st Jan Change
3.35 ^USD	+0.30%		-0.30%	-43.41%

04-04	Morgan Stanley Initiates Coverage on Mural Oncology With Overweight Rating, $13 Price Target	MT
01-08	Mural Oncology plc Announces Enhancements to Late-Stage Clinical Trials	CI

Mural Oncology plc(NasdaqGM:MURA) dropped from NASDAQ Biotechnology Index

December 15, 2023 at 12:00 am

Mural Oncology plc removed from NASDAQ Biotechnology Index.

Latest news about Mural Oncology plc

Morgan Stanley Initiates Coverage on Mural Oncology With Overweight Rating, $13 Price Target	04-04	MT
Mural Oncology plc Announces Enhancements to Late-Stage Clinical Trials	01-08	CI
Mural Oncology plc(NasdaqGM:MURA) dropped from S&P Biotechnology Select Industry Index	12-18	CI
Mural Oncology plc(NasdaqGM:MURA) dropped from NASDAQ Biotechnology Index	12-15	CI
Mural Oncology plc(NasdaqGM:MURA) added to NASDAQ Composite Index	11-17	CI
Mural Oncology plc(NasdaqGM:MURA) added to NASDAQ Biotechnology Index	11-16	CI
Mural Oncology plc(NasdaqGM:MURA) added to S&P TMI Index	11-16	CI
Mural Oncology plc(NasdaqGM:MURA) added to S&P Biotechnology Select Industry Index	11-16	CI
Mural Oncology plc(NasdaqGM:MURA) added to S&P Global BMI Index	11-16	CI

Mural Oncology plc is a clinical-stage oncology company. The Company is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. It leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.

Sector

Biotechnology & Medical Research

Calendar

2024-06-13 - Three Part Advisors East Coast IDEAS Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.35 USD

Average target price

13 USD

Spread / Average Target

+288.06%

Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MURAL ONCOLOGY PLC	-43.41%	56.69M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs